Target intelligence / Profile preview

Transcriptional repressor CTCFL (BORIS) (CTCFL)

Target
CTCFL
Molecular classification
Transcription factor, Cancer-testis antigen, Other
01

Overview

Transcriptional repressor CTCFL, commonly known as Brother of the Regulator of Imprinted Sites (BORIS), is a cancer-testis antigen and a germline-specific paralog of the architectural chromatin protein CTCF. Under normal physiological conditions, BORIS is expressed exclusively during male germ cell development and spermatogenesis, where it plays a critical role in epigenetic reprogramming, gene imprinting, and chromatin remodeling. However, BORIS is aberrantly reactivated and overexpressed in a wide variety of human malignancies, including breast, ovarian, lung, and prostate cancers, particularly within cancer stem cell populations. In these cancer cells, BORIS competes with CTCF for DNA binding sites, disrupting the 3D genome architecture, altering the epigenetic landscape, and driving the expression of oncogenes and other cancer-testis antigens.

Because of its highly restricted expression in normal tissues and widespread activation in cancers, BORIS is considered an ideal target for cancer immunotherapy. Therapeutic strategies under development primarily focus on cancer vaccines, such as DNA vaccines, peptide-loaded dendritic cell therapies, and viral vector-based vaccines (e.g., VRP-mBORIS). To mitigate safety concerns regarding the oncogenic potential of functional BORIS and off-target autoimmune reactions due to the highly conserved zinc finger domain, these immunotherapies typically utilize a modified version of the protein that lacks the DNA-binding domain.

Other names
Brother of the regulator of imprinted sitesCCCTC-binding factor-likeCTCF paralogCTCF-like proteinCancer/testis antigen 27CT27Zinc finger protein CTCF-TBORIS
02

Mechanism of action

Active immunotherapy targeting cancer-testis antigen to induce cytotoxic T-lymphocyte responses against cancer stem cells

03

Biological functions

Transcription regulationEpigenetic regulationCell proliferationSpermatogenesisOther
04

Disease associations

CancerOther
05

Safety considerations

Hypothetical risk of accelerating cancer progression due to DNA-binding and gene-activating functions of functional BORISOff-target immune responses due to high homology of the zinc finger domain with other zinc finger proteinsPotential autoimmune reactions in testis, although the testis is an immune-privileged site
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

CTCFL expressionCTCFL promoter hypomethylationBORIS-specific T-cell response

Beyond the preview

Go deeper on Transcriptional repressor CTCFL (BORIS) (CTCFL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcriptional repressor CTCFL (BORIS) (CTCFL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call